Celemics

Celemics EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Celemics (331920.KQ) as of Oct 15, 2026 is -13.62 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -6.47 % — a change of 110.46% (lower).

EBIT/Assets

-13.62 %

YoY

110.46%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Celemics is 2025 -13.62 % . Operating Income to Assets Ratio (EBIT/Assets) of Celemics was 2024 -6.47 % . It decreases by 110.46% lower compared to the previous year.

The Celemics EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-47.04 KRW
Jan 1, 2019
-70.29 KRW
Jan 1, 2020
-15.99 KRW
Jan 1, 2021
-22.38 KRW
Jan 1, 2022
-25.82 KRW
Jan 1, 2023
-31.85 KRW
Jan 1, 2024
-6.47 KRW
Jan 1, 2025
-13.62 KRW
The Celemics EBIT/Assets history
YEAREBIT/AssetsYoY
-13.62 %+110.46%
-6.47 %-79.68%
-31.85 %+23.37%
-25.82 %+15.37%
-22.38 %+39.90%
-15.99 %-77.24%
-70.29 %+49.41%
-47.04 %-27.01%
-64.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celemics Stock analysis

What does Celemics do? Celemics Inc is a South Korean company based in Seoul, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company provides biotechnology services, focusing on the development and sale of target capture kit products. It also offers immune repertoire analysis solutions and next-generation sequencing solutions. Celemics Inc went public through an IPO on August 21, 2020, and currently employs 63 full-time staff. The company's products are sold in both domestic and international markets. Its headquarters are located in Seoul, South Korea, and it maintains a website at www.celemics.com. The firm's primary business activities include the provision of specialized biotechnology services, with an emphasis on innovative tools and solutions for life science research and applications. Celemics Inc has a presence in the Korean market and extends its reach to global customers, supporting various research and diagnostic needs through its technology-driven services. The company's operational focus remains on developing and delivering advanced biotechnology solutions to meet the evolving demands of the life sciences industry. Celemics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celemics stock

Operating Income to Assets Ratio (EBIT/Assets) of Celemics is -13.62 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Celemics changed from -6.47 % to -13.62 %, representing a 110.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Celemics since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Celemics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Celemics

All Key Metrics — Celemics